Last €111.98 EUR
Change Today -1.23 / -1.09%
Volume 0.0
TN8 On Other Exchanges
Symbol
Exchange
New York
Stuttgart
Mexico
As of 8:07 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TN8) Snapshot

Open
€112.31
Previous Close
€113.21
Day High
€112.80
Day Low
€111.78
52 Week High
01/23/15 - €113.96
52 Week Low
04/29/14 - €81.42
Market Cap
44.8B
Average Volume 10 Days
100.2
EPS TTM
--
Shares Outstanding
400.0M
EX-Date
12/11/14
P/E TM
--
Dividend
€0.55
Dividend Yield
0.41%
Current Stock Chart for THERMO FISHER SCIENTIFIC INC (TN8)

thermo fisher scientific inc (TN8) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. It operates in three segments: Analytical Technologies; Specialty Diagnostics; and Laboratory Products and Services. The Analytical Technologies segment offers instruments, reagents, consumables, software, and services for applications in the laboratory, on the production line, and in the field. It serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The Specialty Diagnostics segment provides various diagnostic test kits, reagents, culture media, instruments, and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. This segment offers blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; human leukocyte antigen typing and testing for the organ transplant; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; and products for cancer diagnosis and medical research in histology, cytology, and hematology applications. The Laboratory Products and Services segment offers sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. The company has a strategic collaboration with Samsung Electronics Co. Ltd. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

50,000 Employees
Last Reported Date: 02/27/14
Founded in 1956

thermo fisher scientific inc (TN8) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $653.7K
Executive Vice President and President of Lab...
Total Annual Compensation: $697.9K
Senior Vice President and President of Analyt...
Total Annual Compensation: $514.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $622.6K
Compensation as of Fiscal Year 2013.

thermo fisher scientific inc (TN8) Key Developments

Thermo Fisher Scientific, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Thermo Fisher Scientific, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. The company reported that for the fourth quarter of 2014, adjusted EPS grew 39% to $1.99, versus $1.43 in the fourth quarter of 2013. Revenue for the quarter grew 30% to $4.49 billion in 2014, versus $3.47 billion in 2013. Organic revenue growth was 6%; acquisitions, net of divestitures, increased revenues by 26% and currency translation reduced revenue by 3%. Adjusted operating income for the fourth quarter of 2014 increased 48% compared with the year-ago quarter, and adjusted operating margin expanded to 22.8%, compared with 20.0% in the fourth quarter of 2013. GAAP diluted EPS for the fourth quarter of 2014 was $1.49, versus $0.92 in the same quarter last year. GAAP operating income for the fourth quarter of 2014 increased 40% to $639 million, compared with $455 million in 2013. GAAP operating margin increased to 14.2%, compared with 13.1% in the fourth quarter of 2013. Income before income taxes was $537.1 million against $377.6 million a year ago. Net income was $601.2 million or $1.49 per diluted share against $342.1 million or $0.92 per diluted share a year ago. Income from continuing operations was $604.0 million or $1.49 per diluted share against $343.0 million or $0.92 per diluted share a year ago. Adjusted net income was $804.7 million or $1.99 per diluted share against $530.3 million or $1.43 per diluted share a year ago. Free cash flow was $827.4 million against $640.4 million a year ago. The company reported that for the full year 2014, adjusted EPS grew 28% to $6.96, versus $5.42 in 2013. Revenue for 2014 grew 29% to $16.89 billion, compared with $13.09 billion a year ago. Organic revenue grew 4%; acquisitions, net of divestitures, increased revenue by 25% and currency translation had a nominal impact. Adjusted operating income for 2014 increased 45% compared with 2013, and adjusted operating margin expanded 240 basis points to 21.9%, compared with 19.5% a year ago. GAAP diluted EPS for 2014 was $4.71, versus $3.48 in 2013. GAAP operating income for 2014 increased 56% to $2.50 billion, compared with $1.61 billion a year ago. GAAP operating margin increased to 14.8%, compared with 12.3% in 2013. GAAP results reflect gains from the sale of businesses in 2014. Net income was $1,894.4 million or $4.71 per diluted share against $1,273.3 million or $3.48 per diluted share a year ago. Income from continuing operations was $1,895.5 million or $4.71 per diluted share against $1,279.1 million or $3.50 per diluted share a year ago. Adjusted net income was $2,800.9 million or $6.96 per diluted share against $1,981.7 million or $5.42 per diluted share a year ago. Free cash flow was $2,245.6 million against $1,753.9 million a year ago. Net cash provided by operating activities was $2,619.6 million against $2,010.7 million a year ago. Purchases of property, plant and equipment were $427.6 million against $282.4 million a year ago. The company is initiating revenue guidance in the range of $16.80 billion to $17.0 billion in 2015, which is about flat with the last year -- with last year and includes a 4.5% headwind from foreign currency. EPS assumes an 8 percentage point headwind from currency, so it is guiding to adjusted EPS of $7.22 to $7.40. This would result in 4% to 6% growth over strong EPS performance in 2014. The company is expecting adjusted income tax rate to be about 14%, down slightly from 14.5% in 2014. It expects net interest expense to be in the range of $375 million to $385 million, about $50 million lower than 2014. The decrease is primarily as a result of continuing to pay down term loan along with settling 2015 maturities, a portion of which will be financed with November 2014 bond issuance. Finally, in terms of full year 2015 free cash flow, it is expecting about $2.6 billion, up $350 million compared to 2014.

Thermo Fisher Scientific Inc. Unveils a New Series of mySPIN Mini Centrifuge

Thermo Fisher Scientific Inc. has unveiled a new series of mySPIN mini centrifuges. The Thermo Scientific mySPIN mini centrifuges are designed for protocols requiring quick spin downs, micro-filter cell separations and HPLC samples as well as applications with a higher RCF requirement. The Thermo Scientific mySPIN 6 and mySPIN 12 mini centrifuges combine speed with flexibility, allowing researchers to easily perform fast spins within 20-30 seconds. In addition, the mySPIN 6 and 12 mini centrifuges feature a compact, ergonomic design to fit personal workstations for daily applications as well as an intuitive display for easy operation. The mySPIN mini centrifuges also offer: Tool-free rotor exchange; Brush-less motor for quiet operation and low vibration; Standard safety features for customer assurance; and Maximum speeds up to 6,000 rpm (mySPIN 6 mini centrifuge) and 12,500 rpm (mySPIN 12 mini centrifuge).

Thermo Fisher Scientific Inc. Launches Next-Generation Sequencing Cancer Research Panel

Thermo Fisher Scientific Inc. has launched a next-generation sequencing (NGS), Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel for targeted sequencing of fusion transcripts for clinical research. The new Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel allows simultaneous sequencing of 70 ALK, RET, ROS1, and NTRK1 fusion transcripts associated with lung cancer as well as 5' and 3' ALK gene expression. Based on Ion Torrent AmpliSeq technology, the NGS fusion detection workflow was designed for simplicity of use and high performance using as little as 10ng of FFPE derived RNA. With the increasing importance of genetic translocations in oncology, the Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel can be used in conjunction with the Ion Torrent AmpliSeq Colon and Lung Cancer Research Panel v2 to obtain a complete view of mutations from even the most limiting lung tissue FFPE samples and fine needle aspirates. The overall approach reduces the cost and risk of sample consumption associated with performing multiple sequential tests as well as the laboratory complexity associated with alternative fusion detection methods such as FISH. The targeted sequencing approach demonstrates high concordance with traditional fusion detection methods, including FISH, ICH, and qPCR. By focusing the sequencing on the fusion junctions, it increases the depth of sequencing on informative regions, enabling higher sensitivity of detection. Integrated with Ion Reporter Software, the application includes easy-to-use fusion reporting and visualization tools for fusion classification.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TN8:GR €111.98 EUR -1.23

TN8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €63.97 EUR -0.31
Becton Dickinson and Co $140.31 USD 0.00
Corning Inc $23.79 USD 0.00
Danaher Corp $83.93 USD 0.00
Safran SA €59.37 EUR -0.37
View Industry Companies
 

Industry Analysis

TN8

Industry Average

Valuation TN8 Industry Range
Price/Earnings 30.0x
Price/Sales 3.1x
Price/Book 2.4x
Price/Cash Flow 30.4x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit www.thermofisher.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.